- Supreme Court extends mifepristone deadlineThe deadliest drug in the country, the new name for PCOS, and more health news from Morning RoundsSTAT · 2mo ago↗ source
- STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’In this edition of STAT Health Tech: Hims earnings, Omada's PBM strategy, and the uphill battle faced by new sepsis algorithms.STAT · 2mo ago↗ source
- STAT+: Hims’ sales miss as telehealth competition growsBristol's partnership with Hengrui Pharma, Viiv loses HIV treatment case, and more biotech news from The ReadoutSTAT · 2mo ago↗ source